Nasus Pharma, Ltd. - היקף יתרות המזומנים של החברה NSRX

The cash reserves of Nasus Pharma Ltd (NSRX), as reported by the GURU.Markets system, correlate with the scaling of nasal technologies for allergy treatment. The latest parameter stands at 0.00, although the risk of failed tests and patent disputes could destabilize the capital. Meanwhile, proprietary protection against price wars in the intranasal systems niche supports the current liquidity of the company.
פילוחי מדדים ואנליטיקה של חברת Nasus Pharma Ltd (NSRX)

Developing innovative intranasal drug delivery systems requires significant capital expenditures in R&D and certification. Analyzing the cash balance allows for tracking the burn rate of liquid reserves without reporting time lags, which determines the ability of Nasus Pharma Ltd (NSRX) to cover its obligations independently. A stable cash reserve guarantees financial stability, although excess liquidity may signal inefficient capital allocation.